Study finds Pfizer's antiviral has little or even zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week - MarketWatch
- Study finds Pfizer's antiviral has little or even zero benefit for younger adults, and WHO says BA.5 omicron subvariant accounted for 74% of cases in latest week MarketWatch
- Pfizer COVID pill provides little or no benefit in adults 40 to 65 USA TODAY
- Pfizer COVID Pill Helped High-Risk Seniors But Showed No Benefit in Younger Adults: Study NBC Chicago
- NEJM Study: Pfizer’s Paxlovid Reduces COVID-19 Death By 81% In Older Adults Health Policy Watch
- Paxlovid reduces risk of COVID-19 death by 81%, Clalit study shows The Jerusalem Post
- View Full Coverage on Google News